22 April 2026

Biologic slashes COPD flare-ups in phase 3 trial

3 minute read

An IL-33–targeting antibody significantly reduced exacerbations in the study, signalling a potential new approach for patients with persistent disease.

This content is for AHPRA registered professionals only.
Login Join Now

End of content

No more pages to load

Register for a new account

Email Address

Password

Confirm Password

First Name

Last Name

Full Name LEAVE THIS BLANK

What field do you work in?

Type of University work:

Industry Specialty:

Other:

Billing Address

First Name

Last Name

Address 1

Address 2

City

State

Postal Code

Country

Phone

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Card Number

Expiration Date /

Security Code (CVC) (what's this?)

I agree to the Terms and conditions and privacy policy *

Processing...

Biologic slashes COPD flare-ups in phase 3 trial

Asthma guides target SABA overuse

Amoxicillin matches clavulanate in sinusitis outcomes

Frequent social media use linked to cannabis use in adolescents

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover

Log in

Register for a new account

Billing Address

Payment Information We Accept Visa, Mastercard, American Express, and Discover